SEC Form 4 · accession 0000899243-16-035267
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roberto Guerciolini
Officer — See Remarks
Period of report
Dec 7, 2016
Accepted (ET)
Dec 9, 2016 · 6:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Dec 7, 2016 | M | 20,000 | $2.47 | A | 20,000 | D | |
| Ordinary Shares | Dec 7, 2016 | M | 4,000 | $2.47 | A | 4,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $2.47 | Dec 7, 2016 | M | 20,000 | D | — | Mar 22, 2025 | Ordinary Shares | 20,000 | 78,617 | D |
| Share Option (Right to Buy)F2 | $2.47 | Dec 7, 2016 | M | 4,000 | D | — | Mar 22, 2025 | Ordinary Shares | 4,000 | 8,629 | D |
Explanation of responses
- F1The incentive share option represented a right to purchase a total of 108,617 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.
- F2The non-qualified option represented a right to purchase a total of 12,629 ordinary shares, 25% of which became exercisable on March 10, 2016, which was the first anniversary on which the option was granted, and the remaining shares vest in 36 equal monthly installments thereafter.
Remarks
Senior Vice President, Head of Early Development